Cited by 378Gastrointestinal motility and disordersPelvic floor disorders treatmentsCongenital gastrointestinal and neural anomalies

Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis

Open access
Ford, Alexander C, Suares, Nicole C·2011·Gut

Abstract

Background: There has been no definitive systematic review and meta-analysis to date examining the effect of laxatives and pharmacological therapies in chronic idiopathic constipation (CIC). Objective: To assess efficacy of these therapies systematically in CIC. Design: Systematic review and meta-analysis of randomised controlled trials (RCTs). Data sources: MEDLINE, EMBASE, and the Cochrane central register of controlled trials were searched (up to September 2010). Eligibility criteria for selecting studies: Placebo-controlled trials of laxatives or pharmacological therapies in adult CIC patients were eligible. Minimum duration of therapy was 1 week. Trials had to report either a dichotomous assessment of overall response to therapy at last point of follow-up in the trial, or mean number of stools per week during therapy. Study appraisal and synthesis methods: Symptom data were pooled using a random effects model. Effect of laxatives or pharmacological therapies compared to placebo was reported as RR of failure to respond to therapy, or a weighted mean difference (WMD) in mean number of stools per week, with 95% CIs. Results: Twenty-one eligible RCTs were identified. Laxatives (seven RCTs, 1411 patients, RR=0.52; 95% CI 0.46 to 0.60), prucalopride (seven trials, 2639 patients, RR=0.82; 95% CI 0.76 to 0.88), lubiprostone (three RCTs, 610 patients, RR=0.67; 95% CI 0.56 to 0.80), and linaclotide (three trials, 1582 patients, RR=0.84; 95% CI 0.80 to 0.87) were all superior to placebo in terms of a reduction in risk of failure with therapy. Treatment effect remained similar when only RCTs at low risk of bias were included in the analysis. Diarrhoea was significantly more common with all therapies. Limitations: Only two RCTs were conducted in primary care, and total adverse events data for laxatives and linaclotide were sparse. Conclusions: Laxatives, prucalopride, lubiprostone and linaclotide are all more effective than placebo for the treatment of CIC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2010.227132

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Prucalopride is efficacious in the treatment of chronic idiopathic constipation, but to date there have been no RCTs in IBS-C.

    “Although prucalopride, which is a highly selective 5-HT 4 agonist with no known cardiovascular or cerebrovascular safety concerns, is efficacious in the treatment of chronic idiopathic constipation, 220 to date there have been no RCTs in IBS-C.”

    From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [220]

    The Response to therapy with prucalopride section reports better outcomes than placebo in chronic idiopathic constipation, supporting efficacy. The paper reviews trials in that condition but does not establish the separate claim that no prucalopride RCTs had been conducted in IBS-C; a search for IBS-C trials found no passage addressing it. Page numbers were not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Although both stimulant and osmotic laxatives are efficacious in the treatment of chronic idiopathic constipation, only the latter have been evaluated in 2 RCTs of polyethylene glycol, recruiting 181 patients with IBS-C.

    “Although both stimulant and osmotic laxatives are efficacious in the treatment of chronic idiopathic constipation, 220 only the latter have been evaluated in 2 RCTs of polyethylene glycol, recruiting 181 patients with IBS-C.221 222”
  • Prucalopride was superior to placebo in chronic constipation.

    “Prucalopride, another 5-HT4 agonist, was superior to placebo in chronic constipation”

    From Irritable bowel syndrome (2020) · cites this paper as [106]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [1]1. Neurogastroenterology on August 20, 2023 by guest. Protected by copyright. http://gut.bmj.com/ Gut: first published as 10.1136/gut.2010.227132 on 4 January 2011. Downloaded from REFERENCES
  2. [20]20. Whitehead WE, Chaussade S, Corazziari E, et al. Report of an international workshop on management of constipation. Gastroenterol Int 1991;4:99e113.
  3. [50]50. Di Palma JA, MacRae DH, Reichelderfer M, et al. Braintree polyethylene glycol (PEG) laxative for ambulatory and long-term care facility constipation patients: report of a randomized, cross-over trial. Online J Dig Health 1999;1:1e7.

Cited by

Sorted by citations

Authors
Ford, A. C., & Suares, N. C.
Affiliations
Leeds General Infirmary (GB)
Venue
Gut
Publisher
BMJ
Published
2011-01-04
Volume
60
Issue
2
Pages
209-218
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2111430126
Cited by
378
References
50
Citations by year
2026: 13 · 2025: 18 · 2024: 17 · 2023: 24 · 2022: 18 · 2021: 20 · 2020: 42 · 2019: 28 · 2018: 30 · 2017: 20 · 2016: 30 · 2015: 13 · 2014: 34 · 2013: 33 · 2012: 20
FWCI
5.57
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Rheumatology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords
chronic idiopathic constipation, laxatives, prucalopride, lubiprostone, linaclotide, pharmacotherapy, treatment efficacy, adverse events, diarrhea
MeSH terms
Lubiprostone, Alprostadil, Benzofurans, Chronic Disease, Constipation, Diarrhea, Humans, Peptides, Randomized Controlled Trials as Topic, Treatment Outcome, Laxatives

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review